Group 1 - Fangda Carbon plans to acquire 100% equity of Tianjin Tongda Huanyu Logistics Co., Ltd. for 319 million yuan [1] - Xiamen Tungsten intends to acquire 39% equity of Jiujiang Dadi Mining Development Co., Ltd. and has signed an intention agreement with a transferor [6] - Wenkai Co. has won a bid for a landscape project worth 50.8162 million yuan [7] Group 2 - Changchun High-tech's subsidiary Jin Sai Pharmaceutical received approval for a clinical trial application for GenSci136, a treatment for IgA nephropathy [3] - China National Pharmaceutical has received drug registration certificates for fumaric acid volnoral tablets, used for treating reflux esophagitis [12] - Zhenhua Group plans to issue convertible bonds not exceeding 1.2 billion yuan [26] Group 3 - CSG Holding's stock may undergo a control change due to share pledge judicial transfer [30] - Ningbo Yunsheng plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [19] - Keda Guochuang's controlling shareholder intends to transfer 5% of the company's shares through an agreement [28] Group 4 - A number of companies, including Finer Pharma, Yixing Guoyuan Investment, and others, have announced plans to reduce their shareholdings by various percentages [2][4][9][11][15][16][20][21][22][23][25][29] - Highweida plans to repurchase shares worth 30 to 35 million yuan [17] - ST Zhongzhu is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [24] Group 5 - A number of companies, including Jiekang Equipment and others, have faced legal issues or penalties [27][40] - Aclaris Therapeutics has clarified that reports regarding its robotic products entering mass production were misinterpreted [41]

Industry News - The Ministry of Transport's new regulatory meeting addressed issues with Gaode Taxi, highlighting management shortcomings and requiring immediate corrective actions to protect driver rights [41] - The Ministry of Commerce held a meeting with automotive companies to discuss strategies for enhancing automotive consumption, including the implementation of a vehicle trade-in program and industry management improvements by 2026 [41] - Apple plans to launch a new iPhone Flip model following the iPhone Fold, prompting Samsung Display to evaluate expanding OLED panel production capacity for Apple [41] - Rare earth product prices have increased, with praseodymium-neodymium oxide averaging 798,800 yuan/ton, up 41,300 yuan/ton; neodymium metal averaging 976,300 yuan/ton, up 61,900 yuan/ton; dysprosium oxide averaging 1,400,800 yuan/ton, up 16,500 yuan/ton; and terbium oxide averaging 6,214,300 yuan/ton, up 77,200 yuan/ton [41][42] Company News - Zhiguang Electric announced a contract for the sale of energy storage systems worth 1.004 billion yuan [43] - Zhejiang Longsheng reported a price increase of 5,000 yuan/ton for certain disperse dyes as of February 8 [43] - Source Technology plans to invest 1.251 billion yuan in the second phase of its optical communication semiconductor chip and device R&D production base [48] - Jinwei Co. intends to acquire 100% of Fusheng Mining for 210 million yuan, with the target company holding mining rights for a production scale of 50,000 tons/year [48]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688247 证券简称：宣泰医药 公告编号：2026-007 上海宣泰医药科技股份有限公司持股5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 大股东持股的基本情况 截至本公告披露日，上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）股东Finer Pharma Inc.（以下简称"Finer"）持有公司股份70,437,870股，占公司总股本的15.5375%。上述股份来源 为公司首次公开发行前取得的股份，已于2025年8月25日解除限售并上市流通。 ● 减持计划的主要内容 公司于2026年2月9日收到Finer出具的《关于上海宣泰医药科技股份有限公司股份减持计划的告知 函》，因股东自身资金需求，Finer计划根据市场情况拟通过集中竞价或大宗交易的方式减持其所持有 的公司股份数量合计不超过9,066,800股，拟减持股份数量占公司总股本的比例不超过2.0000%。其中以 集中竞价方式减持的，减 ...

Group 1 - The controlling shareholder of Bowei Alloy plans to increase its stake in the company by 100 million to 150 million yuan [1] - The actual controller and directors of Congsheng Co. intend to reduce their holdings by no more than 5% of the company's shares [1] - Yinbei Investment of Senba Sensor plans to reduce its stake by no more than 3% of the company's shares [1] Group 2 - The controlling shareholder and its concerted parties of Liansheng Chemical plan to reduce their holdings by no more than 3% of the company's shares [1] - A shareholder of ST Zhongzhu intends to reduce its stake by no more than 3% of the company's shares [1] - Shareholders of Youde Precision (rights protection) plan to collectively reduce their holdings by no more than 3% of the company's shares [1] Group 3 - Shareholder Finer of Xuantai Pharmaceutical plans to reduce its stake by no more than 2% of the company's shares [1] - A shareholder of Far East Co. intends to reduce its holdings by no more than 1.5% of the company's shares [1] - A shareholder of Zhongzhou Special Materials plans to reduce its stake by no more than 1.4% of the company's shares [1] Group 4 - Qianhai Jin控 plans to reduce its stake in GCL-Poly Energy by no more than 1.01% of the company's shares [1] - The controlling shareholder of Keda Technology intends to reduce its holdings by no more than 1% of the company's shares [1] - Yulong Venture Capital plans to reduce its stake in Haiguo Co. by no more than 0.9965% of the company's shares [1] Group 5 - Shareholders of Lian Technology plan to collectively reduce their holdings by no more than 0.96% of the company's shares [1] - The controlling shareholder of Teda Co. intends to reduce its holdings by no more than 29.38 million shares [1] - The actual controller of Perfect World reduced its stake by 1.247 million shares during a period of abnormal stock fluctuations [1] Group 6 - A shareholder of Tengya Precision plans to reduce its stake by no more than 3.8 million shares [1]

宣泰医药(688247.SH)发布公告，公司股东Finer Pharma Inc.(简称"Finer")计划根据市场情况拟通过集中 竞价或大宗交易的方式减持其所持有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司总 股本的比例不超过2%。 ...

Group 1 - Jinwei Co., Ltd. plans to acquire 100% equity of Fusheng Mining for 210 million yuan, which will become a wholly-owned subsidiary and included in the consolidated financial statements [2] - Mengguli intends to invest 929 million yuan to build a project with an annual production capacity of 30,000 tons of lithium-ion battery cathode materials, expected to produce 5,000 tons of high-voltage cobalt acid lithium, 10,000 tons of NCA materials, and 15,000 tons of ultra-high nickel ternary materials [2] - Xiamen Tungsten plans to acquire 39% equity of Jiujiang Dadi Mining, which will help increase mineral resource reserves and improve raw material self-sufficiency [3] Group 2 - Andavil's subsidiary received EASA certification for its aviation kitchen plug-in products, marking compliance with European aviation safety standards [2] - CIMC Vehicles disclosed that the US ITC made a preliminary ruling on anti-subsidy and anti-dumping investigations regarding Van-Type Trailers, indicating potential damage to the US domestic industry [4] - Source Technology plans to invest approximately 1.251 billion yuan to build a second phase project for the R&D and production of optoelectronic communication semiconductor chips and devices [9] Group 3 - Zhongmin Energy intends to acquire 51% equity of Mintou Pumped Storage for 864 million yuan, with the transaction price based on asset evaluation [10] - Ningbo Yunsheng plans to publicly issue H-shares and apply for listing on the Hong Kong Stock Exchange [11] - Wenkai Co., Ltd. won a bid for a landscape project worth 50.8162 million yuan [12] Group 4 - China Merchants Shekou achieved a signed sales amount of 7.674 billion yuan in January 2026 [16] - AVIC Optoelectronics reported a net profit of 2.124 billion yuan for 2025, a year-on-year decrease of 36.69% [17] - Tiankang Bio reported a sales revenue of 392 million yuan from pig sales in January 2026, with a month-on-month increase of 6.23% [18] Group 5 - Poly Developments reported a signed amount of 15.617 billion yuan in January 2026, a year-on-year decrease of 13.31% [19] - Chengtou Holdings reported a net profit of 290 million yuan for 2025, a year-on-year increase of 19.67% [20] - Qianjin Pharmaceutical reported a net profit of 288 million yuan for 2025, a year-on-year increase of 24.74% [21]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

公告显示，Finer持有公司股份7043.79万股，占公司总股本的15.5375%。上述股份来源为公司首次公开 发行前取得的股份，已于2025年8月25日解除限售并上市流通。 北京商报讯（记者 丁宁）2月9日晚间，宣泰医药（688247）发布公告称，因自身资金需求，公司股东 Finer Pharma Inc.（以下简称"Finer"）计划根据市场情况拟通过集中竞价或大宗交易的方式减持其所持 有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司总股本的比例不超过2%。 ...

宣泰医药(688247.SH)发布公告，公司股东Finer Pharma Inc.(简称"Finer")计划根据市场情况拟通过集中 竞价或大宗交易的方式减持其所持有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司总 股本的比例不超过2%。 ...

格隆汇2月9日丨宣泰医药(688247.SH)公布，公司于2026年2月9日收到Finer出具的《关于上海宣泰医药 科技股份有限公司股份减持计划的告知函》，因股东自身资金需求，Finer计划根据市场情况拟通过集 中竞价或大宗交易的方式减持其所持有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司 总股本的比例不超过2.0000%。其中以集中竞价方式减持的，减持期间为本公告披露之日起15个交易日 后的3个月内；以大宗交易方式减持的，减持期间为本公告披露之日起15个交易日后的3个月内。减持价 格按市场价格确定。 ...